AESICA ANNOUNCES PARTNERSHIP WITH BRADFORD UNIVERSITY
Leading pharmaceutical manufacturer, Aesica has announced a partnership with the Centre for Pharmaceutical Engineering Science at the University of Bradford, which will enable the team at Bradford to utilise the GMP capabilities and assets held at Aesica, while Aesica will benefit from the Centres extensive research facilities.
Leading pharmaceutical manufacturer, Aesica has announced a partnership with the Centre for Pharmaceutical Engineering Science at the University of Bradford, which will enable the team at Bradford to utilise the GMP capabilities and assets held at Aesica, while Aesica will benefit from the Centre’s extensive research facilities.
The partnership was formed following a presentation from Dr. Riddhi Shukla, business development manager at the Centre for Pharmaceutical Engineering Science to the Aesica Innovation Board and builds upon the relationship established in 2009 between both parties.
The Centre offers a number of processing technologies including hot melt extrusion, but relies on the GMP expertise of the formulation development team at Aesica to manufacture GMP clinical trial supplies.
Speaking of the partnership, Paul Titley, managing director, Formulation Development, Aesica says: “We provide GMP contract manufacturing services to six other universities, but this partnership is particularly important and unique as it is mutually beneficial. While the team at Bradford has development expertise in several key approaches and as such can evaluate the viability of compounds presented by virtual and small pharma organisations, our GMP expertise is crucial to take the compounds into clinical trials, which is vital. By working with such organisations at an early stage we would hope to cement long term development and manufacturing partnerships and expedite the leap from concept to commercialisation with a clear and proven route to market. In addition, the facilities at the Centre for Pharmaceutical Engineering Science will enable us to further enhance our overall formulation development service offering which will add value to our existing clients.”
Dr. Shukla adds: “Aesica is a well established pharmaceutical company with exemplary GMP credentials, which we were keen to tap into for the benefit of our contacts within the multinational pharma community. Our facilities at the Centre are second to none and we believe this coupled with our research expertise will deliver significant benefits to Aesica as the partnership evolves.”
The partnership follows a sustained period of expansion by Aesica, which has seen the CMO double its workforce and establish three manufacturing sites in Europe and drive forward plans to expand its offer across America. In addition, Aesica recently
announced plans to create up to 100 new jobs at its Queenborough, UK, facility between now and 2015 as the site prepares for significant expansion.
Furthermore, the company was recently ranked in The Sunday Times HSBC International Track 200, a newly created list that ranks Britain’s private companies with the fastest growing international sales. Published in July, the table listed Aesica as the second best performing company in the North East of England after its international sales grew by 37 per cent over the course of the two years to December 2011 - international sales now represent 98 per cent of the company’s overall turnover.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance